COPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ — Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targetedCOPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ — Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted

Curasight to present at TD Cowen’s 46th Annual Health Care Conference in Boston

2026/02/17 15:15
Okuma süresi: 2 dk
Bu içerikle ilgili geri bildirim veya endişeleriniz için lütfen crypto.news@mexc.com üzerinden bizimle iletişime geçin.

COPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ — Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies across multiple aggressive solid tumors, will present recent company progress including the ongoing Phase 1 clinical trial uTREAT® in glioblastoma, at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd, 2026, at 11:50 a.m. Eastern Time / 5:50 p.m. CET in Boston. 

A live audio webcast will be broadcast over the internet simultaneously and will be available in the investor section on Curasight.com approximately 48 hours after the webcast.

During the conference, Curasight management will also hold 1:1 meetings with investors and other industry stakeholders.

The TD Cowen conference is a major investor conference where public and private healthcare companies meet with institutional investors, and large pharma via scheduled 1×1 meetings and presentations combined with fireside chats and innovative panel discussions.

About Curasight A/S

Curasight is advancing uTREAT®, a clinical-stage, first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat solid tumors. uTREAT® targets uPAR, a key driver of tumor invasion, angiogenesis, and metastasis, which is expressed in more than 85% of solid tumors.

The company’s theranostic platform also includes uTRACE®, a uPAR-PET imaging agent built on the same proprietary ligand as uTREAT®. uTRACE® supports patient selection and confirms tumor targeting and has been evaluated in more than 450 patients across nine Phase II trials in eight solid tumor indications.

The uPAR platform is based on more than a decade of research at the Copenhagen University Hospital and the University of Copenhagen.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
E-mail: uk@curasight.com
www.curasight.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/curasight/r/curasight-to-present-at-td-cowen-s-46th-annual-health-care-conference-in-boston,c4308454

The following files are available for download:

https://mb.cision.com/Main/19744/4308454/3937544.pdf

260217 Curasight Press release – TDCowen

Cision View original content:https://www.prnewswire.com/news-releases/curasight-to-present-at-td-cowens-46th-annual-health-care-conference-in-boston-302689307.html

SOURCE Curasight

Piyasa Fırsatı
Cypherium Logosu
Cypherium Fiyatı(CPH)
$0.004869
$0.004869$0.004869
+1.73%
USD
Cypherium (CPH) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen crypto.news@mexc.com ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Why LYNO’s Presale Could Trigger the Next Wave of Crypto FOMO After SOL and PEPE

Why LYNO’s Presale Could Trigger the Next Wave of Crypto FOMO After SOL and PEPE

The post Why LYNO’s Presale Could Trigger the Next Wave of Crypto FOMO After SOL and PEPE appeared on BitcoinEthereumNews.com. Cryptocirca has never been bereft of hype cycles and fear of missing out (FOMO). The case of Solana (SOL) and Pepe (PEPE) is one of the brightest examples that early investments into the correct projects may yield the returns that are drifting. Today there is an emerging rival in the limelight—LYNO. LYNO is in its presale stage, and already it is being compared to former breakout tokens, as many investors are speculating that LYNO will be the next big thing to ignite the market in a similar manner. Early Bird Presale: Lowest Price LYNO is in the Early Bird presale and costs only $0.050 for each token; the initial round will rise to $0.055. To date, approximately 629,165.744 tokens have been sold, with approximately $31,458.287 of that amount going towards the $100,000 project goal.  The crypto presales allow investors the privilege to acquire tokens at reduced prices before they become available to the general market, and they tend to bring substantial returns in the case of great fundamentals. The final goal of the project: 0.100 per token. This gradual development underscores increasing investor confidence and it brings a sense of urgency to those who wish to be first movers. LYNO’s Edge in a Competitive Market LYNO isn’t just another presale token—it’s a powerful AI-driven cross-chain arbitrage platform designed to deliver real utility and long-term growth. Operating across 15+ blockchains, LYNO’s AI engine analyzes token prices, liquidity, volume, and gas fees in real-time to identify the most profitable trade routes. It integrates with bridges like LayerZero, Wormhole, and Axelar, allowing assets to move instantly across networks, so no opportunity is missed.  The platform also includes community governance, letting $LYNO holders vote on protocol upgrades and fee structures, staking rewards for long-term investors, buyback-and-burn mechanisms to support token value, and audited smart…
Paylaş
BitcoinEthereumNews2025/09/18 16:11
The $55 Oil Trade Is Still on the Table, but Brent’s Chart Has Conditions

The $55 Oil Trade Is Still on the Table, but Brent’s Chart Has Conditions

The post The $55 Oil Trade Is Still on the Table, but Brent’s Chart Has Conditions appeared on BitcoinEthereumNews.com. The oil price surged on April 2 as Brent
Paylaş
BitcoinEthereumNews2026/04/02 18:30
Covéa Chooses Shift Technology as Strategic Partner for Fraud and Risk Management

Covéa Chooses Shift Technology as Strategic Partner for Fraud and Risk Management

Covéa has selected Shift Technology as a long-term partner to support a consistent and shared view of risk from policy inception through to claims settlement The
Paylaş
ffnews2026/04/02 07:00

Trade GOLD, Share 1,000,000 USDT

Trade GOLD, Share 1,000,000 USDTTrade GOLD, Share 1,000,000 USDT

0 fees, up to 1,000x leverage, deep liquidity